Back to search

Article

A Phase I trial to evaluate cisplatin, gemcitabine and the mTOR inhibitor temsirolimus for first-line treatment of participants with transitional cell urothelial cancer, or advanced solid cancer

2025-03-27

Abstract excerpt

<title>Abstract</title> <p>Gemcitabine plus cisplatin (GC) is effective in urothelial and other cancers. We investigated GC combined with escalating doses of temsirolimus (T), intravenous mTOR inhibitor. Adults with histologically confirmed solid tumours were enrolled. The primary endpoint was safety of GC with T, including dose limiting toxicity. Exploratory endpoints included pharmacokinetics and circulating tu...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
4a520769-bfab-52de-90b3-38963fe399b2
DOI
10.21203/rs.3.rs-5333803/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 10 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
A Phase I trial to evaluate cisplatin, gemcitabine and the mTOR inhibitor temsirolimus for first-line treatment of participants with transitional cell urothelial cancer, or advanced solid cancerDOI 10.21203/rs.3.rs-5333803/v1
Phase 2 Trial of Gemcitabine, Cisplatin, plus Ipilimumab in Patients with Metastatic Urothelial Cancer and Impact of DNA Damage Response Gene Mutations on Outcomes.Semantic proximity
Defining the mode of action of cisplatin combined with a phosphoramidate modification of gemcitabineSemantic proximity
Innovative In Vitro-In Silico Platform for Dose-Response Modeling in Canine Bladder Cancer: A 3D Organoid- and Mathematics-Based ApproachSemantic proximity
Phase I dose-escalation study of copanlisib in combination with gemcitabine or cisplatin plus gemcitabine in patients with advanced cancer.Semantic proximity
A multicenter phase 1 study of PX-866 and cetuximab in patients with metastatic colorectal carcinoma or recurrent/metastatic squamous cell carcinoma of the head and neck.Semantic proximity
Gastrointestinal and Genitourinary Toxicity Profiles of Metformin Versus Placebo in Men With Prostate Cancer Receiving Pelvic Radiotherapy: Interim Toxicity Results of a Double-blinded, Multicenter, Phase II Randomized Controlled TrialSemantic proximity
A phase I trial of temsirolimus and erlotinib in patients with refractory solid tumors.Semantic proximity
A phase II study of temsirolimus and erlotinib in patients with recurrent and/or metastatic, platinum-refractory head and neck squamous cell carcinoma.Semantic proximity
SLC28A3 genotype and gemcitabine rate of infusion affect dFdCTP metabolite disposition in patients with solid tumours.Semantic proximity
High Sensitivity of an Ha-RAS Transgenic Model of Superficial Bladder Cancer to Metformin Is Associated with ∼240-Fold Higher Drug Concentration in Urine than Serum.Semantic proximity
Select a neighboring publication to make it the new centre.